Key Market Indicator:
F&G: 23
25.437,00 NASDAQ · 47.695,00 DOW · 6.818,20 S&P · 4.222,77 Gold · 62,24 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
DE000A1EWVY8
Filter zurücksetzen
© EQS Newswire
24.11.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
NTC wird Kommerzialisierungspartner für Formycons Eylea®-Biosimilar FYB203/Baiama® in Italien
Article
News Preview
Pressemitteilung // 24. November 2025   NTC wird Kommerzialisierungspartner für Formycons Eylea®-Biosimilar FYB203/Baiama® in Italien   Planegg-Martinsried – Formycon AG (FWB: FYB, “Formycon”) und NTC s.r.l. (“NTC”) geben gemeinsam bekannt, dass die Klinge Biopharma GmbH (“Klinge”), Lizenznehmer und exklusiver Inhaber der weltweiten Vermarktungsr......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.11.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy
Article
News Preview
Press Release // November 24, 2025  NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy   Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) and NTC s.r.l. (“NTC”) jointly announce that Klinge Biopharma GmbH (“Klinge”), the exclusive owner of the global commercialization rights of Formycon......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.11.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
First Berlin Equity Research GmbH: Formycon AG | Rating: Buy
Article
News Preview
Original-Research: Formycon AG - from First Berlin Equity Research GmbH 20.11.2025 / 17:00 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certai......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© EQS Newswire
20.11.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Ranibizumab-Biosimilar Epruvy® ab sofort in Deutschland verfügbar
Article
News Preview
Pressemitteilung // 20. November 2025   Ranibizumab-Biosimilar Epruvy® ab sofort in Deutschland verfügbar   Sandoz vermarktet Epruvy®1 in Deutschland als Fertigspritze (PFS) und Durchstechflasche im Rahmen einer Lizenzvereinbarung mit der Bioeq AG Die neue Fertigspritze kombiniert hohe Qualitätsstandards in der Biosimilar-Entwicklung mit einem b......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
20.11.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Ranibizumab Biosimilar Epruvy® launched in Germany
Article
News Preview
Press Release // November 20, 2025  Ranibizumab Biosimilar Epruvy® launched in Germany   Sandoz commercializes Epruvy®1 in innovative pre-filled syringe (PFS) and vial presentation in Germany under license from Bioeq AG The PFS delivery system represents a key advancement combining biosimilar development excellence with customer-friendly design ......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.11.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Biosimilar-Kandidat für Dupixent® (Dupilumab) als weiterer Wachstumstreiber im Formycon-Portfolio
Article
News Preview
Pressemitteilung // 17. November 2025   Meilenstein bei FYB208 erreicht: Biosimilar-Kandidat für Dupixent® (Dupilumab) als weiterer Wachstumstreiber im Formycon-Portfolio Wichtiger präklinischer Meilenstein Technical Proof of Similarity (TPoS) zeigt hohe analytische Vergleichbarkeit von FYB208 mit Referenzarzneimittel Überzeugende in-vitro Daten......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.11.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Biosimilar candidate for Dupixent® (dupilumab) adds another growth driver to the biosimilar portfolio
Article
News Preview
   Press Release // November 17, 2025   Milestone achieved with FYB208: Biosimilar candidate for Dupixent® (dupilumab) as another growth driver in Formycon's portfolio Important preclinical milestone Technical Proof of Similarity (TPoS) demonstrates high analytical comparability of FYB208 to reference drug Strong in vitro data support cost-effe......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.11.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon veröffentlicht Neunmonatsergebnis und bestätigt Prognose – Pipeline-Fortschritte und starke Partnerschaften prägen Geschäftsjahr 2025
Article
News Preview
Pressemitteilung // 13. November 2025  Formycon veröffentlicht Neunmonatsergebnis und bestätigt Prognose – Pipeline-Fortschritte und starke Partnerschaften prägen Geschäftsjahr 2025 Prognose für 2025 bestätigt – Umsatz- und Ergebnisentwicklung im Rahmen der Erwartungen FYB202 (Stelara®1-Biosimilar): Markterschließung in den USA und Europa schrei......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.11.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon publishes nine-month results and confirms guidance – Pipeline progress and strong partnerships drive fiscal year 2025
Article
News Preview
Press Release // November 13, 2025   Formycon publishes nine-month results and confirms guidance – Pipeline progress and strong partnerships drive fiscal year 2025 Guidance for 2025 confirmed – Revenue and earnings development in line with expectations FYB202 (Stelara®1 biosimilar): Market penetration in the US and Europe continues Significant ......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.10.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
Article
News Preview
Press Release // October 30, 2025   Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025   Planegg-Martinsried, Germany – Formycon AG (FSB: FYB, Prime Standard, „Formycon“) plans to publish its Nine-Month Results 2025 on November 13, 2025. The Management Boar......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.10.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon lädt zur Telefonkonferenz zum Neunmonatsergebnis 2025 ein und gibt Teilnahme an Investorenkonferenzen im 4. Quartal 2025 bekannt
Article
News Preview
Pressemitteilung // 30. Oktober 2025  Formycon lädt zur Telefonkonferenz zum Neunmonatsergebnis 2025 ein und gibt Teilnahme an Investorenkonferenzen im 4. Quartal 2025 bekannt   Planegg-Martinsried – Die Formycon AG (FWB: FYB, Prime Standard, „Formycon“) plant die Neunmonatszahlen 2025 am 13. November 2025 zu veröffentlichen. Der Vorstand wird di......
Themefolio
Profiler
Peergroup
© EQS Newswire
21.10.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
FYB201/Ranivisio® ist das erste Ranibizumab-Biosimilar Europas in einer Fertigspritze
Article
News Preview
Pressemitteilung // 21. Oktober 2025   Formycon setzt neuen Standard: FYB201/Ranivisio® ist das erste Ranibizumab-Biosimilar Europas in einer Fertigspritze Innovative Fertigspritze (PFS) für intravitreale Injektionen¹ bietet verbessertes Handling sowie hohe Dosiergenauigkeit und Anwenderfreundlichkeit Teva Pharmaceutical Industries Ltd. übernimm......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
21.10.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
Article
News Preview
Press Release // October 21, 2025   Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe Innovative pre-filled syringe (PFS) with high standards for intravitreal injections1 offers improved handling, high dosing accuracy and greater convenience for applicants Teva Pharmac......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.10.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
Article
News Preview
Press Release // October 16, 2025  Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America  Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) announces that Klinge Biopharma GmbH (“Klinge”), the exclusive owner of the global c......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.10.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Actor Pharmaceuticals und Megalabs werden Vermarktungspartner für Formycons Eylea®-Biosimilar FYB203 (Aflibercept) in Australien und Lateinamerika
Article
News Preview
Pressemitteilung // 16. Oktober 2025  Actor Pharmaceuticals und Megalabs werden Vermarktungspartner für Formycons Eylea®-Biosimilar FYB203 (Aflibercept) in Australien und Lateinamerika  Planegg-Martinsried – Die Formycon AG (FWB: FYB, “Formycon”) gibt bekannt, dass die Klinge Biopharma GmbH (“Klinge”), Lizenznehmer und exklusiver Inhaber der welt......
Themefolio
Profiler
Peergroup
© EQS Newswire
02.10.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon sichert US-Vermarktungsstart für Aflibercept-Biosimilar FYB203 durch Settlement-Vereinbarung mit Regeneron
Article
News Preview
 Pressemitteilung // 2. Oktober 2025 Formycon sichert US-Vermarktungsstart für Aflibercept-Biosimilar FYB203 durch Settlement-Vereinbarung mit Regeneron Formycon und seine Partner haben mit Regeneron eine Vergleichs- und Lizenzvereinbarung für FYB203/AHZANTIVE®1 (Aflibercept-mrbb) abgeschlossen Die anhängigen Verfahren vor dem US-Bezirksgericht ......
Themefolio
Profiler
Peergroup
© EQS Newswire
02.10.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Article
News Preview
Press Release // October 2, 2025 Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron Formycon and its partners entered into a settlement and license agreement with Regeneron for FYB203/AHZANTIVE® (Aflibercept-mrbb) Pending litigation at the U.S. District Court fo......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
First Berlin Equity Research GmbH: Formycon AG | Rating: Buy
Article
News Preview
Original-Research: Formycon AG - from First Berlin Equity Research GmbH 17.09.2025 / 15:55 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certai......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Horus Pharma wird Zweitvermarktungspartner für Formycons Eylea®-Biosimilar FYB203 unter der Marke Baiama® in ausgewählten europäischen Ländern
Article
News Preview
Pressemitteilung // 17. September 2025  Horus Pharma wird Zweitvermarktungspartner für Formycons Eylea®-Biosimilar FYB203 unter der Marke Baiama® in ausgewählten europäischen Ländern  Planegg-Martinsried – Die Formycon AG (FWB: FYB, „Formycon“) gibt bekannt, dass die Klinge Biopharma GmbH („Klinge“), Lizenznehmer und exklusiver Inhaber der weltwe......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
Article
News Preview
Press Release // September 17, 2025  Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®   Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) announces that Klinge Biopharma GmbH (“Klinge”), the exclusive owner of the global co......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.08.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon confirms full-year guidance following business development in line with plan – working capital raised
Article
News Preview
Press Release // August 13, 2025   Formycon confirms full-year guidance following business development in line with plan – working capital raised Half-year results in line with expectations – full-year 2025 guidance confirmed Outlook for working capital raised following successful placement of oversubscribed €70 million corporate bond Strong se......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.08.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon bestätigt Jahresprognose nach planmäßiger Geschäftsentwicklung und hebt Working Capital an
Article
News Preview
Pressemitteilung // 13. August 2025   Formycon bestätigt Jahresprognose nach planmäßiger Geschäftsentwicklung und hebt Working Capital an Halbjahreszahlen im Rahmen der Erwartungen – Prognose für das Geschäftsjahr 2025 bestätigt Prognostiziertes Working Capital aufgrund erfolgreicher Platzierung einer überzeichneten 70 Mio. € Unternehmensanleihe......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.08.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
First Berlin Equity Research GmbH: Formycon AG | Rating: Buy
Article
News Preview
Original-Research: Formycon AG - from First Berlin Equity Research GmbH 04.08.2025 / 11:45 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certai......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.07.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025
Article
News Preview
Press Release // July 30, 2025   Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025   Planegg-Martinsried, Germany – Formycon AG (FSB: FYB, Prime Standard, „Formycon“) plans to publish its results of the first half of the 2025 fiscal year on Au......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.07.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon lädt zur Telefonkonferenz zu den Ergebnissen des ersten Halbjahres 2025 ein und gibt Teilnahme an internationalen Investorenkonferenzen im 3. Quartal 2025 bekannt
Article
News Preview
Pressemitteilung // 30. Juli 2025  Formycon lädt zur Telefonkonferenz zu den Ergebnissen des ersten Halbjahres 2025 ein und gibt Teilnahme an internationalen Investorenkonferenzen im 3. Quartal 2025 bekannt   Planegg-Martinsried – Die Formycon AG (FWB: FYB, Prime Standard, „Formycon“) plant die Ergebnisse des ersten Halbjahres 2025 am 13. August ......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.07.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon schließt Patientenrekrutierung für die klinische Entwicklung des Keytruda®-Biosimilar-Kandidaten FYB206 erfolgreich ab
Article
News Preview
Pressemitteilung // 10. Juli 2025   Formycon schließt Patientenrekrutierung für die klinische Entwicklung des Keytruda®-Biosimilar-Kandidaten FYB206 erfolgreich ab   Optimiertes klinisches Entwicklungsprogramm, das ohne Phase-III-Studie auskommt, bereits sehr weit fortgeschritten Letzter Patient in Dahlia-Pharmakokinetik-Studie (PK-Studie) einge......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.07.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206
Article
News Preview
Press Release // July 10, 2025   Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206  Streamlined clinical development program, which no longer requires a Phase III trial, is already in a far advanced stage Last patient enrolled in Dahlia pharmacokinetic (PK) study (Last P......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.07.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Bio Usawa wird Vermarktungspartner von FYB201/ BioUcenta™ (Ranibizumab) in der Region Subsahara-Afrika
Article
News Preview
 Pressemitteilung // 1. Juli 2025 Bio Usawa wird Vermarktungspartner von FYB201/ BioUcenta™ (Ranibizumab) in der Region Subsahara-Afrika Partnerschaft markiert einen Meilenstein auf dem Weg zur globalen Verfügbarkeit von FYB201 Bio Usawa erhält exklusive Rechte zur Zulassung und Vermarktung von FYB201/BioUcenta™1 in der Region Subsahara-Afrika ......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.07.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa
Article
News Preview
Press Release // July 1, 2025 Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa Partnership marks a landmark step towards global availability of FYB201 Bio Usawa gets exclusive rights to register and commercialize FYB201/BioUcenta™1 in Sub-Saharan Africa Product launch expected in ......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
Article
News Preview
Press Release // 27. June 2025  Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed Due to strong demand, the offering period for the public offering has been shortened and target volume was increased from initially EUR 50 million to EUR 70 million Interest ......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon erhöht Anleihevolumen nach Überzeichnung – Anleihe 2025/2029 in Höhe von 70 Mio. Euro erfolgreich und vollständig platziert
Article
News Preview
Pressemitteilung // 27. Juni 2025 Formycon erhöht Anleihevolumen nach Überzeichnung – Anleihe 2025/2029 in Höhe von 70 Mio. Euro erfolgreich und vollständig platziert Aufgrund starker Nachfrage Angebotszeitraum des öffentlichen Angebots verkürzt und Zielvolumen von ursprünglich 50 Mio. Euro auf 70 Mio. Euro erhöht Zinssatz in Höhe des EURIBOR pl......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon successfully places an EUR 70 million senior unsecured floating rate bond
Article
News Preview
Disclosure of Inside Information Pursuant to Article 17 of Regulation (EU) No. 596/2014 NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR PUBLICATION MAY BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE ......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon platziert erfolgreich eine unbesicherte und variabel verzinsliche Anleihe in Höhe von EUR 70 Mio.
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014 NICHT ZUR VERBREITUNG, VERÖFFENTLICHUNG ODER WEITERGABE, DIREKT ODER INDIREKT, IN ODER INNERHALB DER VEREINIGTEN STAATEN VON AMERIKA, KANADA, AUSTRALIEN, JAPAN ODER ANDEREN LÄNDERN, IN DENEN DIE VERBREITUNG ODER VERÖFFENTLICHUNG RECHTSWIDRIG SEIN KÖNNTE. ES ......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Teva wird Zweitvermarktungspartner für Formycons Stelara®-Biosimilar FYB202 (Ustekinumab) unter der Marke Fymskina® in Deutschland
Article
News Preview
Pressemitteilung // 26. Juni 2025   Teva wird Zweitvermarktungspartner für Formycons Stelara®-Biosimilar FYB202 (Ustekinumab) unter der Marke Fymskina® in Deutschland   Teva-Tochter Ratiopharm vermarktet Fymskina® als weiteres Formycon Ustekinumab-Biosimilar semi-exklusiv in Deutschland Markteinführung von Fymskina® für das 3. Quartal 2025 gepl......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany
Article
News Preview
Press Release // June 26, 2025   Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany   Teva's subsidiary Ratiopharm is going to commercialize Fymskina® as a second Formycon ustekinumab biosimilar on a semi-exclusive basis in Germany Market launch of F......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
US-Biosimilarspezialist Valorum Biologics LLC wird Kommerzialisierungspartner für Formycons Eylea®-Biosimilar FYB203/AHZANTIVE® (Aflibercept-mrbb) in den Vereinigten Staaten und Kanada
Article
News Preview
Pressemitteilung // 25. Juni 2025   US-Biosimilarspezialist Valorum Biologics LLC wird Kommerzialisierungspartner für Formycons Eylea®-Biosimilar FYB203/AHZANTIVE® (Aflibercept-mrbb) in den Vereinigten Staaten und Kanada  Valorum Biologics, US-Biosimilar-Spezialist mit Fokus auf Augenheilkunde und Onkologie wird FYB203/AHZANTIVE® exklusiv in den ......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® (aflibercept-mrbb) in the United States and Canada
Article
News Preview
Press Release // June 25, 2025   U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® (aflibercept-mrbb) in the United States and Canada   Valorum Biologics, an expert for ophthalmology and oncology biosimilars in the U.S. market, will exclusively commercialize FYB20......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Starke Nachfrage nach Formycon-Anleihe 2025/2029 führt zu Verkürzung der Angebotsfrist
Article
News Preview
Pressemitteilung // 24. Juni 2025 Starke Nachfrage nach Formycon-Anleihe 2025/2029 führt zu Verkürzung der Angebotsfrist Hohe Nachfrage institutioneller Investoren ermöglicht vorzeitiges Ende des öffentlichen Angebotszeitraums Zeichnungsfrist über die Formycon-Webseite endet bereits am 26. Juni 2025, 23:59 Uhr MESZ Zeichnung über DirectPlace de......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period
Article
News Preview
  Press Release // June 24, 2025 Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period High demand by institutional investors enables early termination of public offering period Subscription period via the Formycon website is now scheduled to end  on 26 June 2025, at 11:59 p.m. CEST Subscription via Deutsche B......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Vorzeitiges Ende der Angebotsfrist für Anleihe aufgrund hoher Nachfrage
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014 NICHT ZUR VERBREITUNG, VERÖFFENTLICHUNG ODER WEITERGABE, DIREKT ODER INDIREKT, IN ODER INNERHALB DER VEREINIGTEN STAATEN VON AMERIKA, KANADA, AUSTRALIEN, JAPAN ODER ANDEREN LÄNDERN, IN DENEN DIE VERBREITUNG ODER VERÖFFENTLICHUNG RECHTSWIDRIG SEIN KÖNNTE. ES ......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Public subscription now also possible via Deutsche Börse
Article
News Preview
Press Release // June 20, 2025 Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse The subscription period via Deutsche Börse AG's DirectPlace is now open and will close on 30 June 2025 at 12:00 p.m. CEST (subject to early closure) The unsecured senior bond has a target volume of €50 million and carries a variable i......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Öffentliche Zeichnung jetzt auch direkt über die Deutsche Börse möglich
Article
News Preview
Pressemitteilung // 20. Juni 2025 Formycon-Anleihe 2025/2029: Öffentliche Zeichnung jetzt auch direkt über die Deutsche Börse möglich Zeichnungsfrist via DirectPlace der Deutsche Börse AG läuft ab sofort bis zum 30. Juni 2025, 12:00 Uhr MESZ (vorzeitige Schließung vorbehalten) Die unbesicherte Anleihe hat ein Zielvolumen von 50 Mio. Euro und ist......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Ordentliche Hauptversammlung der Formycon AG stimmt allen Beschlussvorschlägen mit großen Mehrheiten zu
Article
News Preview
Pressemitteilung // 18. Juni 2025   Ordentliche Hauptversammlung der Formycon AG stimmt allen Beschlussvorschlägen mit großen Mehrheiten zu Vorstand berichtet ausführlich über Geschäftsjahr 2024 und gibt Ausblick für 2025 Aufsichtsrat wird auf sechs Mitglieder erweitert; Klaus Röhrig wiedergewählt Dr. Graham Keith Dixon als neues Mitglied in de......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities
Article
News Preview
Press Release // June 18, 2025   Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities Management provides detailed report on financial year 2024 and provides outlook for 2025 Supervisory Board expands to six members; Klaus Röhrig re-elected Dr. Graham Keith Dixon elected as a new member of the Sup......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Zeichnung der Unternehmensanleihe 2025/2029 gestartet
Article
News Preview
Pressemitteilung // 18. Juni 2025 Formycon AG: Zeichnung der Unternehmensanleihe 2025/2029 gestartet Planegg-Martinsried – Die Formycon AG (FWB: FYB, Prime Standard, „Formycon") gibt bekannt, dass der Wertpapierprospekt am 17. Juni durch die luxemburgische Finanzaufsichtsbehörde CSSF gebilligt wurde und die Unternehmensanleihe 2025/2029 (ISIN NO0......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Subscription period for 2025/2029 corporate bond has started
Article
News Preview
Press Release // June 18, 2025 Formycon AG: Subscription period for 2025/2029 corporate bond has started Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) announces that the securities prospectus for the newly issued corporate bond 2025/2029 (ISIN NO0013586024 / WKN A4DFJH) has been approved by the Luxembourg finan......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon plant öffentliche Unternehmensanleihe zur Unterstützung der nächsten Wachstumsphase im attraktiven Biosimilar-Markt
Article
News Preview
Pressemitteilung // 17. Juni 2025   Formycon plant öffentliche Unternehmensanleihe zur Unterstützung der nächsten Wachstumsphase im attraktiven Biosimilar-Markt Unbesicherte Anleihe 2025/2029 hat Zielvolumen von 50 Mio. Euro und ist variabel verzinst Erlöse unterstützen gezielte Weiterentwicklung des Biosimilar-Produktportfolios und die Umsetzun......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets
Article
News Preview
Press Release // June 17, 2025 Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets Unsecured bond 2025/2029 with a target volume of EUR 50 million and variable interest rate Proceeds will support the targeted development of biosimilar product portfolio and the execution of the next grow......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon plant Begebung einer unbesicherten und variabel verzinslichen öffentlich handelbaren Anleihe mit einem Zielvolumen von EUR 50 Mio. zur Unterstützung des weiteren Unternehmenswachstums
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014 NICHT ZUR VERBREITUNG, VERÖFFENTLICHUNG ODER WEITERGABE, DIREKT ODER INDIREKT, IN ODER INNERHALB DER VEREINIGTEN STAATEN VON AMERIKA, KANADA, AUSTRALIEN, JAPAN ODER ANDEREN LÄNDERN, IN DENEN DIE VERBREITUNG ODER VERÖFFENTLICHUNG RECHTSWIDRIG SEIN KÖNNTE. ES ......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth
Article
News Preview
Disclosure of Inside Information Pursuant to Article 17 of Regulation (EU) No. 596/2014 NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR PUBLICATION MAY BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE ......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil
Article
News Preview
Press Release // June 5, 2025    Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil Raniviso® becomes first approved Lucentis® biosimilar in Brazil Commercialization partnership established with Brazilian pharmaceutical company Biomm Product launch in Brazil expected in Q4 2025, kicking off the commercial rollout of FYB201......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Lucentis®-Biosimilar FYB201/Ranivisio® (Ranibizumab) in Brasilien zugelassen
Article
News Preview
Pressemitteilung // 05. Juni 2025   Lucentis®-Biosimilar FYB201/Ranivisio® (Ranibizumab) in Brasilien zugelassen Raniviso® als erstes Lucentis®-Biosimilar in Brasilien zugelassen Kommerzialisierungspartnerschaft mit brasilianischem Pharmaunternehmen Biomm abgeschlossen Produkteinführung in Brasilien ist für das vierte Quartal 2025 geplant und b......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.05.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon und Fresenius Kabi geben Markteinführung des Ustekinumab-Biosimilars FYB202/Otulfi™ in Kanada bekannt
Article
News Preview
Pressemitteilung // 27. Mai 2025   Formycon und Fresenius Kabi geben Markteinführung des Ustekinumab-Biosimilars FYB202/OtulfiTM in Kanada bekannt FYB202/OtulfiTM1 ab sofort in Kanada für subkutane und intravenöse Anwendung verfügbar Der Launch in Kanada stärkt die Marktpräsenz von OtulfiTM über die USA und Europa hinaus und verbessert den Zugan......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.05.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada
Article
News Preview
Press Release // May 27, 2025   Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar, in Canada FYB202/Otulfi™ is now commercially available in Canada in both subcutaneous and intravenous formulations Launch expands market presence beyond the U.S. and Europe, offering broader treatment ......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.05.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
Article
News Preview
Press Release // May 19, 2025 Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)  Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its commercialization partner Fresenius Kabi announce today that the U.S. Food and Drug Administration (FDA) designated F......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.05.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon und Fresenius Kabi geben FDA-Zulassung von FYB202/Otulfi® (Ustekinumab-aauz) als austauschbares Biosimilar („interchangeable“) bekannt
Article
News Preview
Pressemitteilung // 19. Mai 2025 Formycon und Fresenius Kabi geben FDA-Zulassung von FYB202/Otulfi® (Ustekinumab-aauz) als austauschbares Biosimilar („interchangeable“) bekannt   Planegg-Martinsried - Die Formycon AG (FWB: FYB, Prime Standard, „Formycon“) und ihr Kommerzialisierungspartner Fresenius Kabi geben heute bekannt, dass die US-amerikani......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.05.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon reports strong operational performance and financial results for first quarter of 2025
Article
News Preview
Press Release // May 12, 2025 Formycon reports strong operational performance and financial results for first quarter of 2025 Strong operational start to the year with market approvals for FYB203 (Aflibercept) in Europe and the United Kingdom as well as new commercialization partnerships with Teva and Lotus Encouraging market launch of FYB202/Ot......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.05.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon berichtet über erfolgreiches operatives Geschäft und Finanzzahlen für das erste Quartal 2025
Article
News Preview
Pressemitteilung // 12. Mai 2025 Formycon berichtet über erfolgreiches operatives Geschäft und Finanzzahlen für das erste Quartal 2025 Operativ starkes Quartal mit Marktzulassungen für FYB203 (Aflibercept) in Europa und Großbritannien sowie Abschluss neuer Kommerzialisierungspartnerschaften mit Teva und Lotus Vielversprechender Vermarktungsstart......
Themefolio
Profiler
Peergroup
© EQS Newswire
07.05.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon lädt zur Telefonkonferenz zu den Ergebnissen des ersten Quartals 2025 ein und gibt Teilnahme an internationalen Investorenkonferenzen bekannt
Article
News Preview
Pressemitteilung // 07. Mai 2025  Formycon lädt zur Telefonkonferenz zu den Ergebnissen des ersten Quartals 2025 ein und gibt Teilnahme an internationalen Investorenkonferenzen bekannt   Planegg-Martinsried – Die Formycon AG (FWB: FYB, Prime Standard, „Formycon“) plant am 12. Mai die Ergebnisse des ersten Quartals 2025 zu veröffentlichen. Der Vor......
Themefolio
Profiler
Peergroup
© EQS Newswire
07.05.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon invites to conference call on the results of the first quarter of 2025 and announces participation in international investor conferences
Article
News Preview
Presse Release // May 7, 2025Formycon invites to conference call on the results of the first quarter of 2025 and announces participation in international investor conferences   Planegg-Martinsried, Germany – Formycon AG (FSB: FYB, Prime Standard, „Formycon“) plans to publish its results for the first quarter of 2025 on May 12, 2025. The Management......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Monday, 01.12.2025, Calendar Week 49, 335th day of the year, 30 days remaining until EoY.